Clinical Trial Update: Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS) [Phase 2]

View source ↗

Summary

A Phase 2 triple-blind randomized trial in Brazil will evaluate tocilizumab as an adjunct to standard treatment for treatment-resistant major depressive disorde…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder Treatment-resistant

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hospital de Clinicas de Porto Alegre | Conditions: Treatment-Resistant Major Depressive Disorder | Phase 2 | Status: NOT_YET_RECRUITING